ATE361748T1 - 1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2- pyrazoline als cyclooxygenase-2 inhibitoren - Google Patents

1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2- pyrazoline als cyclooxygenase-2 inhibitoren

Info

Publication number: ATE361748T1
Authority: AT; Austria
Prior art keywords: sub; cyclooxygenase; group; inhibitors; aryl
Prior art date: 1999-06-16

Application number

AT00939946T

Other languages

English (en)

Inventor

E Reddy

M Reddy

Original Assignee

Univ Temple

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-16

Filing date

2000-06-16

Publication date

2007-06-15

2000-06-16 Application filed by Univ Temple filed Critical Univ Temple

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE361748T1 publication Critical patent/ATE361748T1/de

Links

239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000004385 trihaloalkyl group Chemical group 0.000 abstract 1
125000004953 trihalomethyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT00939946T 1999-06-16 2000-06-16 1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2- pyrazoline als cyclooxygenase-2 inhibitoren ATE361748T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13941699P	1999-06-16	1999-06-16

Publications (1)

Publication Number	Publication Date
ATE361748T1 true ATE361748T1 (de)	2007-06-15

Family

ID=22486543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00939946T ATE361748T1 (de)	1999-06-16	2000-06-16	1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2- pyrazoline als cyclooxygenase-2 inhibitoren

Country Status (11)

Country	Link
US (2)	US6376519B1 (de)
EP (1)	EP1191931B1 (de)
JP (1)	JP2003501464A (de)
KR (1)	KR100796851B1 (de)
AT (1)	ATE361748T1 (de)
AU (1)	AU771668C (de)
CA (1)	CA2377153A1 (de)
DE (1)	DE60034785D1 (de)
IL (2)	IL146851A0 (de)
NZ (1)	NZ516553A (de)
WO (1)	WO2000076503A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6716991B1 (en) *	1993-11-30	2004-04-06	G. D. Searle & Co.	Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US20040072889A1 (en) *	1997-04-21	2004-04-15	Pharmacia Corporation	Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) *	1998-12-23	2004-06-24	Pharmacia Corporation	Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20030096854A1 (en) *	2002-06-12	2003-05-22	Ho-Shen Lin	Substituted tricyclics
ES2174757B1 (es) *	2001-04-06	2003-11-01	Esteve Labor Dr	Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
US6878729B2 (en) *	2001-05-04	2005-04-12	The Procter & Gamble Company	Medicinal uses of dihydropyrazoles
ES2183720B1 (es)	2001-06-18	2004-01-16	Esteve Labor Dr	Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
WO2003024958A2 (en) *	2001-09-18	2003-03-27	Onconova Therapeutics, Inc.	Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
WO2003024400A2 (en)	2001-09-18	2003-03-27	Onconova Therapeutics, Inc.	Process for the preparation of 1,5-diarylpyrazoles
AU2002337843A1 (en)	2001-10-12	2003-04-22	Onconova Therapeutics, Inc.	Processes for the preparation of substituted isoxazoles and 2-isoxazolines
US20030220374A1 (en) *	2002-01-14	2003-11-27	Pharmacia Corporation	Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) *	2002-01-14	2003-11-13	Pharmacia Corporation	Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
AU2003249597B2 (en)	2002-03-08	2007-06-28	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
AU2003270049A1 (en) *	2002-08-29	2004-03-19	University Of Florida Research Foundation Incorporated	Cox-2 mediated altered prostaglandin balance in diabetes complications
US20040147581A1 (en) *	2002-11-18	2004-07-29	Pharmacia Corporation	Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
DE60332387D1 (de)	2002-12-13	2010-06-10	Warner Lambert Co	Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
US20040220155A1 (en) *	2003-03-28	2004-11-04	Pharmacia Corporation	Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2004093829A2 (en) *	2003-03-31	2004-11-04	Temple University-Of The Commonwealth System Of Higher Education	(-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2
WO2005009342A2 (en) *	2003-07-16	2005-02-03	Pharmacia Corporation	Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) *	2003-08-21	2005-06-02	Pharmacia Corporation	Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005023189A2 (en) *	2003-09-03	2005-03-17	Pharmacia Corporation	Method of cox-2 selective inhibitor and nitric oxide-donating agent
JP2007518788A (ja)	2004-01-22	2007-07-12	ファイザー・インク	バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
ES2238923B1 (es) *	2004-02-16	2006-11-01	Laboratorios Del Dr. Esteve, S.A.	Nuevos derivados pirazolinicos sustituidos.
KR20070044799A (ko) *	2004-02-16	2007-04-30	라보라토리오스 델 드라. 에스테브.에스.에이.	암 치료에 유용한 피라졸린 유도체
TW200533657A (en)	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1740530B8 (de)	2004-03-16	2017-03-01	Temple University - Of The Commonwealth System of Higher Education	Substituierte phenoxy- und phenylthioderivate zur behandlung von proliferativen erkrankungen
CA2563963A1 (en) *	2004-04-28	2005-11-10	Pfizer Inc.	3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
ES2257929B1 (es)	2004-07-16	2007-05-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
US7897589B2 (en)	2005-07-15	2011-03-01	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (de)	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
EP1743890A1 (de)	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
ATE511860T1 (de)	2006-12-22	2011-06-15	Recordati Ireland Ltd	Kombinationstherapie für erkrankungen der unteren harnwege mit 2 liganden und nsar
CN109906082A (zh)	2016-09-07	2019-06-18	塔夫茨大学信托人	使用免疫dash抑制剂和pge2拮抗剂的组合治疗

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2740793A (en)		1956-04-03		Pyrazolines
US2640056A (en)	1949-06-03	1953-05-26	Ilford Ltd	Pyrazoline sulphonic acids
BE788658R (fr) *	1971-09-09	1973-03-12	Hoechst Ag	Derives de 3-(3', 4'-dichloro-6'-alkylphenyl) -delta2-pyrazolines, leurpreparation et leur utilisation comme agents d'azurage
US3836523A (en)	1972-11-03	1974-09-17	Sun Research Development	One-step synthesis of caprolactam
US4045571A (en)	1973-04-17	1977-08-30	Bayer Aktiengesellschaft	Pyrazol-5-ones
DE2452946A1 (de)	1974-11-08	1976-05-13	Merck Patent Gmbh	Pyrazolidinone und verfahren zu ihrer herstellung
US4447442A (en)	1981-07-13	1984-05-08	American Cyanamid Company	3-Trifluoroacetylamino-1-aryl-2-pyrazolines
US4448973A (en)	1981-07-13	1984-05-15	American Cyanamid Company	Therapeutically active 3-substituted amino-1-phenyl and substituted phenyl-2-pyrazolines
US4407803A (en)	1981-08-17	1983-10-04	Abbott Laboratories	Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
AU626881B2 (en)	1988-07-14	1992-08-13	F. Hoffmann-La Roche Ag	Benzofused heterocyclics used as pharmaceuticals
DE3831430A1 (de)	1988-09-15	1990-03-22	Bayer Ag	Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5134148A (en)	1989-02-28	1992-07-28	Imperial Chemical Industries Plc	Heterocycles for use as inhibitors of leukotrienes
DE4126994A1 (de)	1991-08-16	1993-02-18	Basf Ag	(alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen
US5334719A (en)	1992-06-17	1994-08-02	Merck Frosst Canada, Inc.	Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
US5434178A (en)	1993-11-30	1995-07-18	G.D. Searle & Co.	1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5908852A (en)	1994-11-14	1999-06-01	G. D. Searle & Co.	1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5700816A (en)	1995-06-12	1997-12-23	Isakson; Peter C.	Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5756529A (en)	1995-09-29	1998-05-26	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
WO1998056377A1 (en) *	1997-06-13	1998-12-17	Smithkline Beecham Corporation	Novel pyrazole and pyrazoline substituted compounds
US5972986A (en)	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6025353A (en)	1997-11-19	2000-02-15	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AUPP103497A0 (en)	1997-12-19	1998-01-15	Panbio Pty Ltd	Assay apparatus
ES2137138B1 (es) *	1998-05-29	2000-09-16	Esteve Labor Dr	Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.

2000
- 2000-06-16 DE DE60034785T patent/DE60034785D1/de not_active Expired - Lifetime
- 2000-06-16 WO PCT/US2000/016656 patent/WO2000076503A1/en not_active Ceased
- 2000-06-16 CA CA002377153A patent/CA2377153A1/en not_active Abandoned
- 2000-06-16 JP JP2001502836A patent/JP2003501464A/ja active Pending
- 2000-06-16 AT AT00939946T patent/ATE361748T1/de not_active IP Right Cessation
- 2000-06-16 NZ NZ516553A patent/NZ516553A/xx not_active IP Right Cessation
- 2000-06-16 AU AU54951/00A patent/AU771668C/en not_active Ceased
- 2000-06-16 US US09/595,760 patent/US6376519B1/en not_active Ceased
- 2000-06-16 KR KR1020017016170A patent/KR100796851B1/ko not_active Expired - Fee Related
- 2000-06-16 EP EP00939946A patent/EP1191931B1/de not_active Expired - Lifetime
- 2000-06-16 IL IL14685100A patent/IL146851A0/xx active IP Right Grant
2001
- 2001-11-30 IL IL146851A patent/IL146851A/en not_active IP Right Cessation
2003
- 2003-07-29 US US10/630,397 patent/USRE39681E1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1191931A1 (de)	2002-04-03
AU771668B2 (en)	2004-04-01
KR20020015350A (ko)	2002-02-27
DE60034785D1 (en)	2007-06-21
KR100796851B1 (ko)	2008-01-22
AU5495100A (en)	2001-01-02
EP1191931B1 (de)	2007-05-09
NZ516553A (en)	2004-01-30
EP1191931A4 (de)	2002-11-27
JP2003501464A (ja)	2003-01-14
AU771668C (en)	2005-08-11
IL146851A (en)	2008-03-20
WO2000076503A1 (en)	2000-12-21
CA2377153A1 (en)	2000-12-21
USRE39681E1 (en)	2007-06-05
US6376519B1 (en)	2002-04-23
IL146851A0 (en)	2002-07-25

Legal Events

Date	Code	Title	Description
2007-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60034785D1 (en)	2007-06-21	1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2-pyrazoline als cyclooxygenase-2 inhibitoren
EP1527049B8 (de)	2008-10-29	Kondensierte heterozyklische verbindungen als petidase inhibitoren
ATE180468T1 (de)	1999-06-15	Anthranilsäure derivate
DE60001623D1 (de)	2003-04-17	Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
DE60221098D1 (de)	2007-08-23	Kondensierte heterocyclische derivate
GB9801690D0 (en)	1998-03-25	Therapeutic agents
BG101422A (bg)	1997-11-28	Бензоксазолни производни като бронхоразширяващи средства
DE69912581D1 (de)	2003-12-11	Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
WO2001017963A3 (en)	2001-11-15	Aminoalkoxy carbazoles and their use as 5-ht ligands
AU7517400A (en)	2001-04-24	N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
NO994960L (no)	1999-12-09	Tricykliske forbindelser
ATE403653T1 (de)	2008-08-15	Pyridin-substituierte furanderivate als raf- kinase inhibitoren
DE69810760D1 (de)	2003-02-20	Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
TR200201128T2 (tr)	2002-08-21	PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
AU2001255646A1 (en)	2001-11-12	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
ATE167855T1 (de)	1998-07-15	Propensäure derivate verwendbar als fungizide
CA2285535A1 (en)	1998-11-12	Benzimidazole derivative for treating allergy-related disease
DK0630367T3 (da)	2000-09-18	Hidtil ukendte arylindazoler og deres anvendelse som herbicider
ES2191621T3 (es)	2003-09-16	Tienocicloalqu(en)ilamino-1,3,5-triazinas substituidas.
WO2000077169A3 (en)	2001-07-05	(z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
WO2000020399A3 (de)	2000-07-27	Verwendung von substituierten 5-hydroxypyrazolen, neue 5-hydroxypyrazole, verfahren zu deren herstellung, sowie sie enthaltende mittel
ATE243695T1 (de)	2003-07-15	5-bicycloindolverbindungen
ES2184633A1 (es)	2003-04-01	Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
ATE289316T1 (de)	2005-03-15	1-(2,5'-anhydro-lyxofuranosyl) thymine zur synthese von radiomarkierten fluor-3' deoxynucleotiden
SE9901237D0 (sv)	1999-04-06	Novel use